Biologic significance of reduced levels of glucose degradation products.
Rippe
B
B
Department of Nephrology, University Hospital of Lund, Sweden. Bengt.Rippe@njur.lu.se
Wieslander
A
A
D001692:Biological Transport; D018394:CA-125 Antigen / Q000032:analysis; D015314:Dialysis Solutions / Q000737:chemistry*; D005947:Glucose / Q000032:analysis*; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006801:Humans; D006820:Hyaluronic Acid / Q000032:analysis; D008875:Middle Aged; D010446:Peptide Fragments / Q000032:analysis; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010537:Peritoneum / Q000378:metabolism; D011347:Procollagen / Q000032:analysis; D011446:Prospective Studies
D018394:CA-125 Antigen; D015314:Dialysis Solutions; D017127:Glycation End Products, Advanced; D010446:Peptide Fragments; D011347:Procollagen; C041876:procollagen Type III-N-terminal peptide; C042813:procollagen type I carboxy terminal peptide; D006820:Hyaluronic Acid; D005947:Glucose